Comparison of two regimens of Insulin and Insulin-Metformin in glycemic control of type 2 Diabetic patients after CABG surgery

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201008084365N5

Enrollment

100

Registered

2011-01-21

Start date

2010-10-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Non-insulin dependent diabetes

Interventions

Intervention 1: Control group: regular insulin infusion according to the center protocol, as well as two placebo tablet every 12 hours. Intervention 2: Intervention group: regular insulin infusion acc

Placebo

Treatment - Drugs

Control group: regular insulin infusion according to the center protocol, as well as two placebo tablet every 12 hours

Intervention group: regular insulin infusion according to the center protocol, as well as two 500 mg metformin tablets every 12 hours

Eligibility

Sex/Gender

All

Age

35 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Informed written consent, Elective CABG surgery, Type 2 diabetes, Age between 35 and 75 years, Use of the cardiopulmonary pump during surgery, Hemodynamic stability (MAP> 60, absence of dangerous dysrhythmia or heart rate between 50-11) Exclusion criteria: Liver dysfunction (SGPT and SGOT greater than 75), Renal dysfunction (serum creatinine greater than 1.5 in two consecutive tests), Heart failure (ejection fraction less than 30 percent), Serum lactate greater than 5mmo /l or increased more than 2mmol /l, Serum PH less than 7.25 or BE less than 6 mmol /l, Arterial oxygen partial pressure less than 60 mm Hg in two consecutive ABG, Use of contrast or angiography during two days before surgery, Potassium less than 3 meq/L, Nausea and vomiting, Use of metformin metabolism Inhibitor drugs such as amiodarone and cimetidine, Use of high dose inotropes more than three hours after extubation, Prolonged intubation (more than 6 hours after surgery), Need for reoperation for any reason

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Blood sugar. Timepoint: every 2 hours. Method of measurement: mg/dl-labratory kit.	—

Secondary

Measure	Time frame
Lactate. Timepoint: every 2 hours. Method of measurement: mg/dl-laboratory kit.;PH. Timepoint: every 2 hours. Method of measurement: laboratory kit.;Base Exess. Timepoint: every 2 hours. Method of measurement: mmol/l, Laboratory kit.;Creatinine. Timepoint: every 6 hours. Method of measurement: mg/dl-laboratory kit.;Potassium. Timepoint: when infused. Method of measurement: meq-form.;Insulin. Timepoint: when infused. Method of measurement: unit-form.	—

Measure

Time frame

Lactate. Timepoint: every 2 hours. Method of measurement: mg/dl-laboratory kit.;PH. Timepoint: every 2 hours. Method of measurement: laboratory kit.;Base Exess. Timepoint: every 2 hours. Method of measurement: mmol/l, Laboratory kit.;Creatinine. Timepoint: every 6 hours. Method of measurement: mg/dl-laboratory kit.;Potassium. Timepoint: when infused. Method of measurement: meq-form.;Insulin. Timepoint: when infused. Method of measurement: unit-form.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Emami Zeidi

Mazandaran University Of Medical Sciences

amie_ei@yahoo.com+98 15132612458

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026